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Abstract
Background: Locally advanced rectal cancer can be down staged by neoadjuvant therapy and the resultant tumor response can 
be quantified histologically. This study aimed to assess pathological response of  neoadjuvant chemoradiation in patients with 
locally advanced rectal cancers treated in Wad Medani Teaching Hospital (WMTH) and National Cancer Institute (NCI), Wad 
Medani, Sudan.
Patients and methods: A total of  36 consecutive patients with locally advanced rectal cancer that were managed in WMTH and 
NCI during the period from 2006-2011 were reviewed. Preoperative pelvic radiotherapy was delivered. Total of  46 Gray were 
delivered concurrently with 5- fluorouracil (5-FU) on the first and last week of  radiation. Total mesorectal excision of  the rectal 
tumour either by anterior or abdominoperineal resections was planned at 6-8 weeks from completion of  preoperative treatment. 
The pathological response to therapy was assessed by histopathology examination of  the surgical specimen.
Results: Initial clinical staging of  patients revealed 58.3% of  them were stage T3/T4N2M0 and 41.7% were stage T3N0M0. 
Down-staging to stage T1/T2N0M0 was found in 36.1% and stage T3N0M0 in 30.6%. No response was seen in 8.3% of  cases 
with stage T3/T4N2M0 while complete clinical response (no residual) was seen in 25.0%. Complete histological response was 
observed in 13.8%. Positive lymph-nodes metastasis was confirmed in 8.3% of  cases.
Conclusion: Neoadjuvant chemoradiation is a reasonable option for cases of  rectal cancer and deserves further evaluation.
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Introduction
Rectal cancer accounts for nearly 30% of  all colorectal 
cancers cases1. Surgical resection is the cornerstone of  
curative therapy. Following a potentially curative resec-
tion, the 5-year survival rate varies according to disease 
extent2,3. After establishing the diagnosis and complet-
ing the staging work-up, a decision is made whether to 
pursue immediate resection or administer preoperative 
chemoradiotherapy(CMRT)4.
The use of  preoperative radiotherapy (RT) combined or 
not with chemotherapy (CM) has been used in the treat-
ment of  rectal cancer for the past two decades and its use 
gradually increased as adjuvant therapy, especially in T3/
T4 and/or N1/N2 tumors5,6. The strategy of  performing 
preoperative instead of  postoperative treatment, has the 
proven advantages of  lower acute toxicity7, lower total 
dose of  radiation needed8 and eventual tumor regression 
and down-staging to enable curative resection and even 
sphincter preservation8-13.
The objective of  this study is to assess the pathological 
response of  neoadjuvant chemo radiation in patients with 
locally advanced rectal cancers treated in WMTH & NCI 
in the period 2006-2011 and to compare our results with 
the reported standards.
Patients and methods
This is a retrospective review of  patients with locally ad-
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vanced rectal cancer that were managed in WMTH and\
or NCI during the period from 2006-2011. In all 36 pa-
tients records are revised for symptoms. Digital rectal 
examination findings for all patients were recorded pre-
operatively at the combined onco-surgical clinic, and all 
patients biopsy from the mass were taken as punch bi-
opsies either bed side or during endoscopic examination. 
Radiological examination was performed evaluating the 
stage of  the tumor and TNM staging system was used.
Neoadjuvant chemo radiation regimens were as follows: 
Pelvic radiotherapy delivered with total central dose of  46 
Gray in 23 sessions. Bolus 5-FU was delivered (400 mg/
m2) during the first and last weeks of  radiation. 5-fluo-
rouracil was given 30 minutes prior to radiation sessions.
All patients had been seen at the combined clinic after 6-8 
weeks of  radiation. Clinical and radiological assessments 
were then repeated. Finally, the combined clinic decided 
on type of  surgery according to the initial site of  the tu-
mor and response to treatment.
Review of  the postoperative histopathology report took 
place addressing the presence of  cancer or viable malig-
nant cells, extent of  invasion and number of  involved 
lymph nodes, a modified pathologic staging system was 
used. The Rectal Cancer Regression Grade (RCRG), 
which simplified the classification to three levels, RCRG 
1: the tumor is either sterilized or only microscopic foci 
of  adenocarcinoma remain; RCRG 2: marked fibrosis, but 
with macroscopic tumor still present; and RCRG 3: little 
or no fibrosis in the presence of  abundant macroscopic 
tumor. RCRG 1 and 2 were considered to represent sig-
nificant tumor regression14. Report included presence of  
lymph-nodes and if  they were involved or not. Data was 
introduced and analyzed by computer program (SPSS 
version 17). To determine the statistical significance of  
differences, the Pearson test was used and probability test 
(P. value) with p < 0.05 considered as significant.
Results
The total number of  cases was thirty six with female to 
male ratio of  1.25:1. All patients were seen in combined 
clinic. More than 55% of  cases have tumor less than 4 cm 
from the anal verge (Figure 1).
In this study, 97.2% (n=35) of  patients received full 
course of  CMRT and the dose of  radiation ranging be-
tween 45-50 Gray Pre and post neoadjuvant therapy clini-
cal staging is shown in (Table 1).
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In this study 91.7% of  cases underwent APR, 8.3% cases 
underwent Anterior Resection (AR)   which was done us-
ing staplers and one patient offered no surgery. Post neo-
adjuvant therapy histological assessment showed RCRGI 
in 41.7% of  cases [of  them 5 out of  15 there were com-
plete sterilization of  the specimen. 13.8%] , RCRGII in 
27.8%, and RCRGIII in 30.6%.
Only 8.3% were found to have metastatic lymph nodes 
deposits. In cross tabulation between the results of  the 
histology post CMRT and the grade of  the tumors, we 
found that a significant relationship (P=0.031) between 
patients grade and response (Table 2).
Discussion
Advances in colorectal cancer treatment create a devel-
opment of  a neoadjuvant CMRT which became widely 
accepted now15. Neoadjuvant CMRT is very effective in 
reducing the tumor mass as seven out of  36 cases showed 
no palpable mass, per digital rectal examination (DRE), 
after neoadjuvant CMRT. All cases were amenable for 
surgery after neoadjuvant CMRT including those who 
presented with fixed tumor (69.4%). This reflected the 
effectiveness of  neoadjuvant CMRT in this study.
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The results of  this study can be compared with Dunst et 
al study done in Germany16 who found clinical response 
rate of  68% (95% confidence interval: 57-78%), and they 
have used a total irradiation dose of  50.4-55.8 Gray with 
conventional fractions. Capecitabine was given at an oral 
dosage of  825 mg/m2 bid on each day of  the radiother-
apy period with the first daily dose applied 2 h before 
irradiation, followed by surgery 6 weeks later16.
In this series 58.3% of  patients (n=21) were found to 
have stage T3/T4N2M0 and post therapy, only 3 cases 
had this stage 8.3% and in 41.7% of  patients (n=15) with 
stage T3N0M0 prior to treatment, the down-staging was 
seen in (13/15). Radiological complete resolution was ob-
served in 25.0% of  cases. The overall down-staging in 
this study was observed in (31/36). In comparison with a 
study done by Rashid A et al they showed down-staging 
was found in 56.7% of  cases17. Duke’s university study 
showed down-staging in 82% of  cases, and this was com-
patible with our findings18.
In a study conducted in Shanghai (2001-2005) published 
in 2007, 105 patients were studied, of  these 13 patients 
showed complete tumor response after neoadjuvant ther-
apy and they spared the operation19. In our study, we were 
following the case who experienced complete clinical and 
pathological response, and who remained free since 2009. 
Pathological complete response which was observed in 
this study was comparable to the findings of  Dunst et al16 
they have pathologically complete response was achieved 
in six patients (7%, 95% confidence interval: 3-14%). 
In another study conducted in Karachi; Rashid A et al 
found that pathological complete resolution of  tumor 
was achieved in 3.3%17.
In cross tabulation between the results of  the histology 
post CMRT and the grade of  the tumors, we found a 
significant relationship (P=0.031) between patients 
grade and response. Eleven out of  15 tumors with grade 
I showed RCRGI, on the other hand only 3 out of  16 
tumors grade 2 showed RCRGII, while only one tumor 
with grade 3 (out of  five) showed complete response 
RCRGIII. This signifies that the tumor grade may predict 
the response to treatment (Table 2).
In 8.3% of  our patients there were lymph nodes retrieved 
in the specimen after surgical resection, this correlates 
well with the series reported by De laFuente SG et al20, 
who found fewer total lymph-nodes were retrieved in the 
neoadjuvant therapy patients compared to those who did 
not receive preoperatively therapy (Neo 14.6 +/- 0.6 vs. 
No-Neo 17.2 +/- 1.1).
In conclusion, neoadjuvant chemoradiation in locally 
advanced rectal cancer in Sudanese patients provide a 
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